Research Advances of Extrachromosomal Circular DNA in Breast Cancer
Cancer Medicine · 2025-10 · 14 (19)
DOI: 10.1002/cam4.71285 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 06.10.2025. Verfasst von Xiaodan Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, China. Hauptthemen laut MEDLINE: DNA, Circular, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Support Program for young and middle-aged people of Wuxi Health Committee, Project supported by the Natural Science Foundation of Jiangsu Province, China, Natural Science Foundation of Nanjing University of Chinese Medicine.
Abstract (Originalsprache)
Background
This article presents an extensive review of the advancements in research concerning extrachromosomal circular DNA (ecDNA) within the context of breast cancer. As a distinct form of DNA, ecDNA is critically involved in the initiation, progression, diagnosis, and treatment of breast cancer.
Methods
The article provides a comprehensive analysis of the mechanisms underlying the formation of ecDNA, highlighting factors such as aberrant DNA damage repair and chromosomal rearrangements. It further examines the biological roles of ecDNA in augmenting oncogene expression, fostering tumor heterogeneity, and facilitating immune evasion.
Results
Epidemiological studies indicate significant variability in the distribution of ecDNA across different breast cancer subtypes, with a notable association with invasive subtypes, such as triple‐negative breast cancer. The presence of ecDNA is linked to poor prognosis and treatment resistance in patients. Current detection technologies for ecDNA include molecular biology and imaging techniques, and its detectability in plasma underscores its potential as a biomarker for liquid biopsy.
Conclusions
The development of ecDNA‐targeted therapies and their integration with immunotherapy strategies offers promising new avenues for breast cancer treatment. Despite challenges such as incomplete elucidation of mechanisms, standardization of detection methods, and ethical considerations, ecDNA remains a valuable biomarker and therapeutic target in breast cancer. Future research is anticipated to advance its clinical transformation and application in individualized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, China.
ORCID-Profile: Yiyang Qian, Chunhui Jin
Förderung
- Talent Support Program for young and middle-aged people of Wuxi Health Committee
- Project supported by the Natural Science Foundation of Jiangsu Province, China
- Natural Science Foundation of Nanjing University of Chinese Medicine
Zitieren
APA
Zhu, X., Qian, Y., Tang, Q., Li, J., Geng, Y., Gong, S., & Jin, C. (2025). Research Advances of Extrachromosomal Circular DNA in Breast Cancer. Cancer Medicine, 14(19). https://doi.org/10.1002/cam4.71285
Vancouver
Zhu X, Qian Y, Tang Q, Li J, Geng Y, Gong S, et al. Research Advances of Extrachromosomal Circular DNA in Breast Cancer. Cancer Medicine. 2025;14(19). doi:10.1002/cam4.71285
BibTeX
@article{Zhu2025,
author = {Zhu, Xiaodan and Qian, Yiyang and Tang, Quan and Li, Jiahui and Geng, Yuqing and Gong, Shixia and Jin, Chunhui},
title = {Research Advances of Extrachromosomal Circular DNA in Breast Cancer},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {19},
doi = {10.1002/cam4.71285}
}
EUVIMED